Head-To-Head Contrast: Cynosure (CYNO) versus The Competition
Cynosure (NASDAQ: CYNO) is one of 74 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its peers? We will compare Cynosure to similar businesses based on the strength of its profitability, valuation, earnings, risk, dividends, analyst recommendations and institutional ownership.
This table compares Cynosure and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings for Cynosure and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cynosure currently has a consensus target price of $58.00, indicating a potential downside of 12.12%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.71%. Given Cynosure’s peers stronger consensus rating and higher probable upside, analysts clearly believe Cynosure has less favorable growth aspects than its peers.
Valuation & Earnings
This table compares Cynosure and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Cynosure Competitors||$2.22 billion||$239.78 million||-30.08|
Cynosure’s peers have higher revenue and earnings than Cynosure. Cynosure is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
53.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 2.9% of Cynosure shares are held by insiders. Comparatively, 17.6% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Cynosure peers beat Cynosure on 7 of the 10 factors compared.
Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
Receive News & Stock Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related stocks with our FREE daily email newsletter.